FDA Signals Interest In Requiring Unique Biosimilar Names
This article was originally published in The Pink Sheet Daily
Executive Summary
OND Director Jenkins expresses concern at a public hearing that the agency could miss or confuse some spontaneous adverse events if biosimilars are not distinguished from their reference product.